SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors discuss Tether's recent $5.7 million investment and broader commitments to Rumble's advertising and cloud services. The community anticipates a potential short squeeze, fueled by high short interest and Tether's increased stake in the company, with some speculating on a year-end rally.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

FET is gaining attention as traders discuss its strong recovery and potential within the AI narrative, particularly its advantageous supply and real-world partnerships. Community members highlight FET's relative strength compared to other altcoins, suggesting it's poised for significant gains once BTC stabilizes. The focus remains on its AI dominance and potential for price discovery, drawing comparisons to previous bullish runs of other tokens.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network ($ZBCN) is trending as the community discusses potential partnerships and its integration with NatPay, which gives Zebec access to real-world payment infrastructure. Bullish sentiment is fueled by the possibility of major exchange listings and the potential for ISO 20022 compliance. However, some traders express concerns about token unlocks and broader market volatility.

Intuition is the L2 for trusted data, and the world's first token-curated graph—allowing people and machines to get the information they need, when they need it, from the sources they trust. With Intuition, you can put your 'intuition' to work—transforming your thoughts, opinions, and experiences into fuel for personalized AI, recommendations, and ads that truly understand you. You fully control your digital identity and data—the most valuable resources of the digital age—enabling you to fully leverage their value while unlocking and democratizing trillions in economic potential. Bring your social graphs, preferences, and 'intuition' with you wherever you go. No more rebuilding your profile and connections from scratch on every new platform—create and curate a universal, portable identity and context that allows applications and AI across the web to understand you instantly. And as you contribute, you’re not just improving your own experience—you’re enhancing the web for everyone who follows and trusts your perspective.

Trust Community Token

Trust Community Token ($TRUST) is trending as some traders celebrate recent gains, while others express concerns about potential losses and volatility. Community members are actively discussing where to buy the token and are optimistic about its long-term potential, with some drawing comparisons to other popular cryptos. Newly listed tokens on major exchanges, along with platform functionality, has put the spotlight on tokens like TRUST.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus ($PMV) is trending as community members express bullish sentiment and promote the meme coin. The community is focused on spreading the "infection" of $PMV, particularly within the $SOL and $PUMP ecosystems. Discussions highlight the coin's potential for growth and strong community engagement.

Blockchain-on-Blockchain (BOB) is a new blockchain built on top of another blockchain called ICP. It's like a special layer on an existing system. BOB creates a secure digital record book that uses ICP's network for safety. BOB uses a system called 'proof-of-on-chain-work': You deploy your own smart contract (canister) at bob.fun. This program solves math problems (hashes). Main computers (mother nodes) give out these problems. Miners solve the problems and tell the mother node. If correct, the mother node adds a new block to the blockchain. The winning miner gets BOB tokens as a reward.

BOB is gaining attention as a novel token built on the ICP blockchain, with some community members drawing parallels to early Bitcoin and highlighting its limited supply. Discussions revolve around its potential within the ICP ecosystem and speculation about future listings and price appreciation. Some users believe that BOB could outperform ICP and become a key driver of network revenue.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternate care testing sites. The Nutritional Products segment caters to the worldwide sales of pediatric and adult nutritional products. The Medical Devices segment includes a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Abbott Laboratories

Abbott is trending due to its planned acquisition of Exact Sciences ($EXAS) for approximately $23 billion, with community discussions focusing on the deal's potential impact on Abbott's cancer diagnostics business and whether a bidding war could emerge. The community is analyzing the strategic rationale and potential synergies, particularly regarding cancer screening technologies. Options traders are actively trading ABT calls and puts, indicating expectations for near-term volatility.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is trending as the crypto market experiences volatility, leading to community discussions about potential bottom levels and future price action. Some investors express frustration with LINK's performance compared to Bitcoin, while others remain optimistic about its long-term potential due to real-world integrations and upcoming events like the SWIFT integration.

Forum Energy Technologies, Inc. designs, manufactures, and distributes products to the oil and natural gas industry. It operates through the Drilling and Completions and Artificial Lift and Downhole segments. The Drilling and Completions segment designs, manufactures and supplies products and solutions to the drilling, subsea, coiled tubing, well stimulation and intervention markets, including applications in oil and natural gas, renewable energy, defense and communications. The Artificial Lift and Downhole segment designs, manufactures and supplies products and solutions for the artificial lift, production and infrastructure markets. The company was founded in 2005 and is headquartered in Houston, TX.

Forum Energy Technologies Inc

Forum Energy Technologies (FET) is trending amidst community discussion around its cash generation, potential for share buybacks, and debt management strategies. Community members are analyzing the impact of the Variperm acquisition and potential catalysts for future growth. Some traders point to the technical setup while others remain cautious, awaiting further confirmation of the company's financial performance and the potential return of capital to shareholders.

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

Tenax Therapeutics Inc

TENX is trending due to high volume and upcoming presentation of Phase 3 data, igniting speculation of a potential squeeze. Community chatter highlights low float, significant institutional ownership, and comparisons to other Steve Cohen-backed stocks like CDTX. Some traders suggest the company may be a takeover target, given its current financial position and potential for FDA approval.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Moderna (NASDAQ:MRNA) Sets New 12-Month Low - Here's Why

Moderna (NASDAQ:MRNA) Reaches New 12-Month Low - Here's Why...

Top Biotech Stocks To Consider - November 20th

Abivax, Cidara Therapeutics, Danaher, Vertex Pharmaceuticals, argenex, Moderna, and Cogent Biosciences are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

22,410 Shares in Moderna, Inc. $MRNA Acquired by Catalyst Funds Management Pty Ltd

Catalyst Funds Management Pty Ltd bought a new stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the...

Walmart, Intuit, The Gap, SanDisk And Moderna: Why These 5 Stocks Are On Investors' Radars Today

WMT, INTU, GAP, SNDK, MRNA were the stocks seen trending on Thursday, Nov. 20, 2025.read more...

What's Going On With Moderna Stock?

Shares of Moderna are falling Thursday. The company made two significant announcements regarding its finances and business strategy.read more...

<ul class="summary-bullets"><li>Moderna said that the five-year term loan facility will strengthen its balance sheet and provide increased flexibility going forward.&nbsp;</li><li>The company continues to target cash breakeven by 2028 and to reduce its expected cash costs for 2026 and 2027.</li><li>It will build a vaccine franchise with as many as six approved products by 2028 and invest cash generated to diversify its portfolio. &nbsp;</li></ul>Vaccine maker Moderna (MRNA) said on Thursday that it has secured a $1.5 billion, five-year credit facility from Ares Management Credit Funds as it seeks to pivot into oncology and rare-disease therapeutics.The company is now eyeing 10% revenue growth in 2026. It said that the five-year term loan facility will strengthen its balance sheet and provide increased flexibility going forward.The initial tranche of $600 million, of three tranches, will be drawn upfront, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=9002529460187539&amp;symbol=MRNA">said</a>, followed by the option to avail $400 million through November 2027. The company can also draw another $500 million through November 2028 under the credit facility contingent on the achievement of key regulatory milestones.<h2 class="st-heading-2">Moderna’s Near-Term Goals</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=5758345706655596&amp;symbol=MRNA">continues</a> to target cash breakeven by 2028 and reduce its 2026 and 2027 expected cash costs with cost management and by prioritizing certain research and development efforts.Moderna rose to fame during the COVID-19 pandemic with its mRNA-based vaccine Spikevax. In the third quarter of 2025, the company reported total revenue of $1 billion, down from $1.9 billion in the corresponding period of 2024, mainly due to lower COVID-19 vaccine sales. However, Covid vaccine sales accounted for a whopping 97% of the company’s overall revenue in the three months through the end of September."Over the next three years, we expect to build a large seasonal vaccine franchise for at-risk populations and invest the cash generated into oncology and rare disease therapeutics," CEO Stéphane Bancel said on Thursday.The company will build a vaccine franchise with as many as six approved products by 2028 and invest cash generated from its portfolio, including Spikevax, mRESVIA and mNEXSPIKE, as well as other yet-to-launch vaccines, including a flu-covid combination vaccine, into diversifying its portfolio.Investment in late-stage oncology and rare disease programs will set the company up for additional growth in 2027 and 2028, the company said.Moderna’s pipeline currently consists of two oncology therapies and two rare disease therapeutics that are under development. It discontinued four programs, including those for congenital Cytomegalovirus, herpes simplex virus, Varicella-Zoster virus and Glycogen Storage Disease Type 1a (GSD1a) as part of its efforts to prioritize some research investments.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MRNA">MRNA stock</a> remained in the ‘bearish’ territory, while message volume dropped from ‘low’ to ‘extremely low’.MRNA stock is down by 42% this year and by 35% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pacs-group-stock-soars-premarket-on-completion-of-audit-commitee-probe-upbeat-full-year-guidance/cLPAjZFREa9">PACS Group Stock Soars Premarket On Completion Of Audit Committee Probe, Upbeat Full-Year Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

Moderna Secures $1.5B Credit Facility As It Seeks To Pivot Away From Vaccines

The company is now eyeing 10% revenue growth in 2026.

Equity

<ul class="summary-bullets"><li>According to Moderna, the onshoring will support both commercial and clinical supply and create hundreds of jobs with over $140 million in investment.&nbsp;</li><li>The new investment is aimed at allowing the company to control the entire production process.</li><li>Other popular pharma companies have also recently committed large amounts to expanding U.S. manufacturing, including Pfizer, Eli Lilly, and Johnson &amp; Johnson.</li></ul>Moderna, Inc. (MRNA) on Wednesday announced that it will bring drug product manufacturing to its existing Moderna Technology Center in Norwood, Massachusetts, as it seeks to operate end-to-end manufacturing for its mRNA medicines in the U.S."By onshoring Drug Product manufacturing to our campus in Norwood, Massachusetts, we have completed the full manufacturing loop under one roof in the U.S.," <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=5477880263899463&amp;symbol=MRNA">said</a> CEO Stéphane Bancel. According to Cambridge-based Moderna, the onshoring will support both commercial and clinical supply and create hundreds of jobs with over $140 million in investment.<h2 class="st-heading-2">Timeline For New Facility</h2>The company said it has commenced construction at the facility in Massachusetts to incorporate drug product manufacturing capability, which is slated for completion in the first half of 2027.The move comes as the company seeks to reduce its reliance on contract manufacturers. The new investment is aimed at allowing the company to control the entire production process.Other popular pharma companies have also recently committed large amounts to expanding U.S. manufacturing, including Pfizer, Eli Lilly, and Johnson &amp; Johnson, as they seek to reduce reliance on overseas manufacturing.<h2 class="st-heading-2">Moderna’s mRNA Candidates</h2>Moderna rose to fame during the COVID-19 pandemic with its mRNA-based vaccine Spikevax. In the third quarter of 2025, the company reported total revenue of $1 billion, down from $1.9 billion in the corresponding period of 2024, mainly due to lower COVID-19 vaccine sales.However, Covid vaccine sales accounted for a whopping 97% of the company’s overall revenue in the three months through the end of September.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MRNA stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<a href="https://stocktwits.com/symbol/MRNA">MRNA stock</a> is down 41% this year and 34% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/kzia-stock-soars-after-company-stage-iv-cancer-patients-shows-initial-complete-remission-on-its-drug-combination/cLPoQdMREBN">KZIA Stock Soars After Stage IV Cancer Patient Shows Initial Complete Remission On Its Drug Combination</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, Moderna’s logo is displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Moderna Brings Back Drug Product Manufacturing To Home Ground

The company said it has commenced construction at the Massachusetts facility, which is slated for completion in the first half of 2027.

If Demographics Are Destiny... We're Screwed!

If Demographics Are Destiny... We're Screwed! Authored by Jim Quinn via The Burning Platform blog, Demographics don't lie. The governments of the world and their captured bureaucrats can manipulate...

Moderna, Inc. $MRNA Stock Position Lifted by Letko Brosseau & Associates Inc.

Letko Brosseau & Associates Inc. boosted its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 2.4% in the second quarter, according to the company in its most recent filing with the Securities...

MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?

Merck rebounds on pipeline wins and a $9.2B Cidara deal, but mixed trends and Keytruda risks keep investors weighing next moves.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

MRNA
Moderna Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MRNA News

MRNAModerna Inc